In vitro evaluation of acyclovir/chitosan floating systems

Materials

Volumn 3, Issue 12, 2010, Pages 5195-5211

  Ruiz Caro, Roberto ^a   Veiga, María D ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Unidad de Biotransformaciones Industriales   (Spain)

Author keywords

Acyclovir; Chitosan; Controlled release; Floating freeze dried formulations; Swelling behavior

Indexed keywords

ACYCLOVIR; CONTROLLED RELEASE; FREEZE-DRIED FORMULATIONS; FREEZE-DRYING PROCESS; IN-VITRO DISSOLUTION; MANUFACTURING PROCESS; PHYSIOLOGICAL STATE; SWELLING BEHAVIOR;

CHITOSAN; DISSOLUTION; DRUG DELIVERY; MOORING; SUSPENSIONS (FLUIDS); VIRUSES; X RAY DIFFRACTION;

SWELLING;

EID: 84860010499     PISSN: None     EISSN: 19961944     Source Type: Journal    
DOI: 10.3390/ma3125195     Document Type: Article

References (57)

1. Illum, L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 1998, 15, 1326-1331.
2. Skaugrud, O. Chitosan--New biopolymer for cosmetics and drugs. Drug Cosmetic Ind. 1991, 148, 24-29.
3. Ilango, R.; Jayakar, B.; Kavimani, S. Chitosan as a new pharmaceutical excipient. The East. Pharm. 1998, 41, 47-49.
4. Singla, A.K.; Chawla, M. Chitosan: some pharmaceutical and biological aspects-an update. J. Pharm. Pharmacol. 2001, 53, 1047-1067.
5. Burkatovskaya, M.; Castano, A.P.; Demidova-Rice, T.N.; Tegos, G.P.; Hamblin, M.R. Effect of chitosan acetate bandage on wound healing in infected and noninfected wounds in mice. Wound Repair Regen. 2008, 16, 425-431.
6. Chen, C.L.; Wang, Y.M.; Liu, C.F.; Wang, J.Y. The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials 2008, 29, 2173-2182.
7. Seyfarth, F.; Schliemann, S.; Elsner, P.; Hipler, U.C. Antifungal effect of high- and lowmolecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl-D-glucosamine against Candida albicans, Candida krusei and Candida glabrata. Int. J. Pharm. 2008, 353, 139-148.
8. Gallaher, D.D.; Gallaher, C.M.; Mahrt, G.J.; Carr, T.P.; Hollingshead, C.H.; Hesslink, R., Jr.; Wise, J. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J. Am. Coll. Nutr. 2002, 21, 428-433.
9. Chiang, M.T.; Yao, H.T.; Chen, H.C. Effect of dietary chitosans with different viscosity on plasma lipids and lipid peroxidation in rats fed on a diet enriched with cholesterol. Biosci. Biotechnol. Biochem. 2000, 64, 965-971.
10. Ubaidulla, U.; Khar, R.K.; Ahmad, F.J.; Sultana, Y.; Panda, A.K. Development and characterization of chitosan succinate microspheres for the improved oral bioavailability of insulin. J. Pharm. Sci. 2007, 96, 3010-3023.
11. Lueßen, H.L.; Lehr, C.M.; Rentel, C.O.; Noach, A.B.J.; de Boer, A.G.; Verhoef, J.C.; Junginger, H.E. Bioadhesive polymers for the peroral delivery of peptide drugs. J. Control. Release 1994, 29, 329-338.
12. Lueßen, H.L.; de Leeuw, B.J.; Langemeÿer, M.W.; de Boer, A.G.; Verhoef, J.C.; Junginger, H.E. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 1996, 13, 1668-1672.
13. Lueßen, H.L.; Rentel, C.O.; Kotzé, A.F.; Lehr, C.M.; de Boer, A.G.; Verhoef, J.C.; Junginger, H.E. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Release 1997, 45, 15-23.
14. Hassan, E.E.; Gallo, J.M. A simple rheological method for the in vitro assessment of mucinpolymer bioadhesive bond strength. Pharm. Res. 1990, 7, 491-495.
15. Kofuji, K.; Shibata, K.; Murata, Y.; Miyamoto, E.; Kawashima, S. Preparation and drug retention of biodegradable chitosan gel beads. Chem. Pharm. Bull. 1999, 47, 1494-1496.
16. Ganza-González, A.; Anguiano-Igea, S.; Otero-Espinar, F.J.; Blanco Méndez, J. Chitosan and chondroitin microspheres for oral-administration controlled release of metoclopramide. Eur. J. Pharm. Biopharm. 1999, 48, 149-155.
17. Shantha, K.L.; Harding, D.R.K. Preparation and in-vitro evaluation of poly[N-vinyl-2-pyrrolidone-polyethylene glycol diacrylate]-chitosan interpolymeric pH-responsive hydrogels for oral drug delivery. Int. J. Pharm. 2000, 207, 65-70.
18. Park, S.H.; Chun, M.K.; Choi, H.K. Preparation of an extended-release matrix tablet using chitosan/Carbopol interpolymer complex. Int. J. Pharm. 2008, 347, 39-44.
19. Nunthanid, J.; Laungtana-Anan, M.; Sriamornsak, P.; Limmatvapirat, S.; Puttipipatkhachorn, S.; Lim, L.Y.; Khor, E. Characterization of chitosan acetate as a binder for sustained release tablets. J. Control. Release 2004, 99, 15-26.
20. Zerrouk, N.; Mennini, N.; Maestrelli, F.; Chemtob, C.; Mura, P. Comparison of the effect of chitosan and polyvinylpyrrolidone on dissolution properties and analgesic effect of naproxen. Eur. J. Pharm. Biopharm. 2004, 57, 93-99.
21. Park, K.M.; Bae, J.W.; Joung, Y.K.; Shin, J.W.; Park, K.D. Nanoaggregate of thermosensitive chitosan-Pluronic for sustained release of hydrophobic drug. Colloids Surf. B. 2008, 63, 1-6.
22. Lim Soo, P.; Cho, J.; Grant, J.; Ho, E.; Piquette-Miller, M.; Allen, C. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: Effect of swelling, degradation and morphology. Eur. J. Pharm. Biopharm. 2008, 69, 149-157.
23. McConnell, E.L.; Murdan, S.; Basit, A.W. An Investigation into the Digestion of Chitosan (Noncrosslinked and Crosslinked) by Human Colonic Bacteria. J. Pharm. Sci. 2008, 97, 3820-3829.
24. Bonferoni, M.C.; Sandri, G.; Rossi, S.; Ferrari, F.; Gibin, S.; Caramella, C. Chitosan citrate as multifunctional polymer for vaginal delivery. Evaluation of penetration enhancement and peptidase inhibition properties. Eur. J. Pharm. Sci. 2008, 33, 166-176.
25. Strauss, E.G.; Strauss, J.H. Viruses and Human Disease, 1st ed.; Academic Press: San Diego, CA, USA, 2002.
26. Whitley, R.J. Herpes simplex virus. In Fields virology, 4th ed.; Knipe, D.M.; Howley, P.M., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA, USA, 2001; pp. 2461-2511.
27. Whitley, R.J.; Roizman, B. Herpes simplex virus infections. Lancet 2001, 357, 1513-1518.
28. Spruance, S.L.; Overall, J.C., Jr.; Kern, E.R.; Krueger, G.G.; Pliam, V.; Miller, W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N. Engl. J. Med. 1977, 297, 69-75.
29. Norval, M.; el-Ghorr, A.A. UV radiation and mouse models of herpes simplex virus infection. Photochem. Photobiol. 1996, 64, 242-245.
30. Erlich, K.S.; Mills, J.; Chatis, P.; Mertz, G.J.; Busch, D.F.; Follansbee, S.E.; Grant, R.M.; Crumpacker, C.S. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1989, 320, 293-296.
31. Corey, L.; Spear, P.G. Infections with herpes simplex viruses (1). N. Engl. J. Med. 1986, 314, 686-691.
32. Corey, L.; Spear, P.G. Infections with herpes simplex viruses (2). N. Engl. J. Med. 1986, 314, 749-757.
33. Erlich, K.S. Management of herpes simplex and varicella-zoster virus infections. West. J. Med. 1997, 166, 211-215.
34. Fujioka, Y.; Mizuno, N.; Morita, E.; Motozono, H.; Takahashi, K.; Yamanaka, Y.; Shinkuma, D. Effect of age on the gastrointestinal absorption of acyclovir in rats. J. Pharm. Pharmacol. 1991, 43, 465-469.
35. Meadows, K.C.; Dressman, J.B. Mechanism of acyclovir uptake in rat jejunum. Pharm. Res. 1990, 7, 299-303.
36. Vergin, H.; Kikuta, C.; Mascher, H.; Metz, R. Pharmacokinetics and bioavailability of different formulations of acyclovir. Arzneimittelforschung 1995, 45, 508-515.
37. de Miranda, P.; Krasny, H.C.; Page, D.A.; Elion, C.B. Species differences in the disposition of acyclovir. Am. J. Med. 1982, 73, 31-35.
38. Collins, P.; Bauer, D.J. Relative potencies of anti-herpes compounds. Ann. N. Y. Acad. Sci. 1977, 284, 49-59.
39. Krenitsky, T.A.; Hall, W.W.; de Miranda, P.; Beauchamp, L.M.; Schaeffer, H.J.; Whiteman, P. 6-Deoxy acyclovir: a xanthine oxidase-activated prodrug of acyclovir. Proc. Natl. Acad. Sci. USA 1984, 81, 3209-3213.
40. Lycke, J.; Malmeström, C.; Ståhle, L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob. Agents Chemother. 2003, 47, 2438-2441.
41. Luengo, J.; Aránguiz, T.; Sepulveda, J. Preliminary pharmacokinetic study to different preparations of acyclovir with β-cyclodextrin. J. Pharm. Sci. 2002, 91, 2593-2598.
42. Attia, I.A.; El-Gizawy, S.A; Fouda, M.A.; Donia, A.M. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech. 2007, 8, E106.
43. Lewis, L.D.; Fowle, A.S.; Bittiner, S.B.; Bye, A.; Isaacs, P.E. Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. Br. J. Clin. Pharmacol. 1986, 21, 459-462.
44. Özdemir, N.; Ordu, S.; Özkan, Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations. Drug Dev. Ind. Pharm. 2000, 26, 857-866.
45. Hoffman, A.; Stepensky, D.; Lavy, E.; Eyal, S.; Klausner, E.; Friedman, M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int. J. Pharm. 2004, 277, 141-153.
46. Gröning, R.; Cloer, C.; Georgarakis, M.; Müller, R.S. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. Eur. J. Pharm. Sci. 2007, 30, 1-6.
47. Sheth, P.R.; Tossounian, J.L. Novel sustained release tablet formulations. U.S. Patent 4,167,558, 1979.
48. Junyaprasert, V.B.; Pornsuwannapha, S. Floating properties and release characteristics of hollow microspheres of acyclovir. Drug Deliv. 2008, 15, 331-341.
49. Gröning, R.; Berntgen, M.; Georgarakis, M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur. J. Pharm. Biopharm. 1998, 46, 285-291.
50. Whitehead, L.; Fell, J.T.; Collett, J.H.; Sharma, H.L.; Smith, A.M. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Control. Release 1998, 55, 3-12.
51. Talukder, R.; Fassihi, R. Gastroretentive delivery systems: hollow beads. Drug Dev. Ind. Pharm. 2004, 30, 405-412.
52. US FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid dosage forms based on a biopharmaceutics classification system. 2000. Available online: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/uc m070246.pdf (accessed on 1 September 2010).
53. Dressman, J.B.; Berardi, R.R.; Dermentzoglou, L.C.; Russell, T.L.; Schmaltz, S.P.; Barnett, J.L.; Jarvenpaa, K.M. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 1990, 7, 756-761.
54. Russell, T.L.; Berardi, R.R.; Barnett, J.L.; Dermentzoglou, L.C.; Jarvenpaa, K.M.; Schmaltz, S.P.; Dressman, J.B. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm. Res. 1993, 10, 187-196.
55. Lui, C.Y.; Amidon, G.L.; Berardi, R.R.; Fleisher, D.; Youngberg, C.; Dressman, J.B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 1986, 75, 271-274.
56. Arora, S.; Ali, J.; Ahuja, A.; Khar, R.K.; Baboota, S. Floating drug delivery systems: a review. AAPS PharmSciTech 2005, 6, E372-E390.
57. Haupt, S.; Zioni, T.; Gati, I.; Kleinstern, J.; Rubinstein, A. Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur. J. Pharm. Sci. 2006, 28, 204-211.